Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101
- SBIJI Innovation
- Sep 29, 2020
- 1 min read
Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate
Read More
Comments